Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients

  • Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-threatening symptoms1
     
  • Patients reported on average more than 5 vaso-occlusive crises (VOCs) per year with serious impact on their quality of life (QoL), including emotional well-being and daily life, as well as ability to work and complete education1,2
     
  • Sickle Cell World Assessment Survey (SWAY), one of world’ …
/by

Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy

  • Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1
     
  • QMF149 showed improvement in peak expiratory flow, exacerbation rates, rescue medication use versus mometasone furoate among other secondary endpoints1   
     
  • Improvement in lung function was observed in high dose QMF149 versus a high dose LABA/ICS standard-of-care in certain additional secondary endpoints1 

 

…

/by

Novartis R&D Day

Our drug discovery and development engine has the scope and scale to innovate the next generation of medicines. We’re harnessing powerful and advanced therapy platforms to take on big scientific challenges and find opportunities to develop breakthrough medicines for patients.

Learn more in our media release.

…
/by

Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day

  • Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms
  • 60 projects in Phase 2 pipeline with 10+ advancing into Phase 3 or pivotal trials each year in 2020 and 2021; over 90% projected to be first-in-class or first-in-indication
  • Emerging assets address areas of high unmet need including iscalimab in transplant and Sjögren’s syndrome, LNP023 in renal diseases and PNH, MBG453 in MDS, and TQJ230 in cardiovascular risk reduction
  • …
/by

Novartis tender offer for The Medicines Company commences

Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has commenced a cash tender offer to purchase all of the outstanding shares of common stock, par value USD 0.001 per share, of The Medicines Company (NASDAQ: MDCO) for a price of USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding (the “Offer”).  The Offer is being made upon the terms and subject to the conditions set forth in the Offer to …

/by

Amazon Web Services (AWS) Announces Strategic Collaboration with Novartis to Accelerate Digital Transformation of its Business Operations

On Wednesday December 4, 2019 Amazon Web Services announced a strategic collaboration with Novartis that will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business operations.  Starting within Novartis Technical Operations, this multiyear alliance aims to put real-time analytics in the hands of associates, empowering them to make better business decisions and increase efficiencies across manufacturing processes and supply chain.

…

/by

Amazon Web Services (AWS) Announces Strategic Collaboration with Novartis to Accelerate Digital Transformation of its Business Operations

On Wednesday December 4, 2019 Amazon Web Services announced a strategic collaboration with Novartis that will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business operations.  Starting within Novartis Technical Operations, this multiyear alliance aims to put real-time analytics in the hands of associates, empowering them to make better business decisions and increase efficiencies across manufacturing processes and supply chain.

…

/by

Behind the research driving our data at medical conferences

At the American Society of Hematology (ASH) Annual Meeting & Exposition and the San Antonio Breast Cancer Symposium (SABCS) in December, Novartis will present more than 180 abstracts. 

We have a rich history of research and development (R&D) in the areas of hematology and oncology. For decades, we have leveraged learnings from both successes and setbacks to broaden our understanding of unmet patient needs, and identify ways to help transform the standard of care for those with blood disorders and cancer. Some of these scientific insights, combined with the information and …

/by

Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms

  • With more than 140 abstracts, Novartis continues its leadership in hematology innovation
     
  • Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in patients with high-risk MDS and AML
     
  • Safety and efficacy data for Kymriah® (tisagenlecleucel)* in real-world setting compared to pivotal trials in relapsed/refractory ALL and DLBCL
     
  • Adakveo® (crizanlizumab) post-hoc analyses of hospitalization data from the SUSTAIN study and interim …
/by

Novartis opens facility for innovative cell and gene therapies in Switzerland

In the presence of Federal Councillor Alain Berset and other distinguished guests, Novartis inaugurated a new manufacturing facility for cell and gene therapies at Stein, Switzerland on November 28th.

“Our site in Stein is vital for new launches of solid and liquid drugs,” said Steffen Lang, Global Head of Novartis Technical Operations and member of the Novartis Executive Committee. “The construction of the new manufacturing facility is another investment in the production of breakthrough cell-based therapies that can potentially change the lives of patients.”

In addition to …

/by